Effects of a Mindfulness-Based Intervention on Circulating Cytokine Levels in Individuals with Amnestic Mild Cognitive Impairment: A Pilot Study

Valérie Morin-Alain, Eddy Larouche, Anne-Marie Chouinard, Marie-Claude Audet, Sonia Goulet, Louis-Simon Rousseau, Carol Hudon

1. CERVO Brain Research Centre, Québec, Canada; E-Mails: valerie.morin-alain.1@ulaval.ca; eddy.larouche.1@ulaval.ca; anne-marie.chouinard.2@ulaval.ca; Sonia.Goulet@psy.ulaval.ca; louis-simon.rousseau.1@ulaval.ca; Carol.Hudon@psy.ulaval.ca
2. School of Psychology, Université Laval, Québec, Canada
3. School of Nutrition Sciences, University of Ottawa, Ottawa, Canada; E-Mail: Marie-Claude.Audet@theroyal.ca
4. Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada

* Correspondence: Valérie Morin-Alain; E-Mail: valerie.morin-alain.1@ulaval.ca

Academic Editor: Gerhard Litscher

Abstract
Peripheral inflammation plays an important role in the pathophysiology of Alzheimer’s disease (AD) and dysregulations in circulating levels of different inflammatory mediators are detectable as early as the mild cognitive impairment (MCI) stage towards AD. Depressive symptoms, another risk factor of AD, are often found in individuals with MCI and associated with heightened levels of peripheral inflammatory mediators. Diminution in depressive symptoms and alterations of peripheral inflammation profiles have been observed following Mindfulness-based interventions (MBIs). In this pilot randomized-control trial, the impact of a mindfulness-based intervention (MBI) was compared to that of a psychoeducation-based intervention (PBI) on the peripheral inflammation profile and depressive symptomatology of participants with MCI. Plasma samples and scores on the Geriatric Depression scale (GDS) were obtained from 12 participants per group before and after the 8-week interventions.
Flow cytometry allowed for inter-group comparisons of the pro-inflammatory cytokines Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)-α levels. Post-MBI, two tendencies stand out regarding inflammation profiles: 1) a decrease of TNF-α for participants having higher initial levels of this cytokine, and 2) an increase of IL-6 levels for all participants. In the PBI group, the cytokine levels remained unchanged post-intervention. Regarding depressive symptomatology, no significant variations were noted for both groups. Moreover, variations on depressive symptoms and peripheral levels of cytokines were not correlated. MBI could exert a physiological effect on an important feature of AD, namely inflammation. Furthermore, action mechanisms behind physiological and psychological effects of MBIs could stem from independent sources. This remains to be demonstrated with more robust data.

Keywords
Mindfulness; mild cognitive impairment; Alzheimer’s disease; peripheral inflammation; cytokines; interleukin-6; tumor necrosis factor alpha; depressive symptoms

1. Introduction

Alzheimer’s disease (AD) is characterized by cognitive decline (most commonly involving memory deficits), with significant impairment of activities of daily living [1]. No effective treatment is currently available to reverse or stop the progression of AD. In light of the many failed attempts at developing effective treatments, hope is now put in primary and secondary prevention strategies targeting modifiable risk factors of AD such as depression, anxiety, smoking, diabetes, hypertension, obesity, cognitive inactivity, low educational attainment, physical inactivity, and inflammation at early stages of the disease [2-7].

Peripheral inflammation as a modifiable risk factor of AD has ramifications crucial for the evolution of the disease. First, inflammation is an underlying common denominator of multiple other risk factors of AD [8, 9]. As illustrated by the allostatic load theory [10], the accumulation of adverse factors (e.g. depression, anxiety, hypertension) over time may impact the homeostasis of the immune system by promoting a chronic state of low-grade systemic inflammation [9]. Second, this chronic inflammatory state may actively contribute to the pathophysiological processes of AD and their repercussions in the brain. Indeed, neuroinflammation, an otherwise beneficial defense mechanism of the brain, becomes chronically overactivated in AD and damages brain tissues, therefore contributing to neurodegeneration and progression of the disease [11, 12].

A growing body of evidence indicate that systemic blood levels of pro-inflammatory cytokines are elevated in AD patients compared to healthy controls, particularly interleukin (IL)-6 and tumor necrosis factor (TNF)-α [13]. Heightened levels of these cytokines increase the risk for developing AD and tend to increase to higher ranges as the disease progresses, making them potential candidates as biomarkers of AD [13, 14]. Some studies reported heightened levels of these cytokines, but to a lesser extent, in individuals suffering from Mild Cognitive Impairment (MCI) when compared to healthy controls [15-18].
MCI corresponds to the prodromal phase of AD in a large subset of individuals [19]. Cognitive functioning in MCI is inferior to what can be expected for the age and level of education of the person, but not sufficient to cause a significant impact on daily functioning [20]. Individuals with MCI are excellent candidates for AD secondary preventive strategies since they show early signs or characteristics of the disease on which one can intervene. Interventions that target inflammation are believed to be more effective for AD prevention in people at risk if they are conducted early in the progression of the disease [21]. According to a multicentric longitudinal study by Breitner and collaborators [22], asymptomatic elderly with a genetic AD predisposition who took nonsteroidal anti-inflammatory drugs (NSAIDs) daily over the course of two years had a lower risk of developing AD within the next two to three years. However, taking NSAIDs at later stages of AD has been associated with an acceleration of the disease progression, suggesting that the preventive effects of NSAIDs could be limited to the early stages of the disease. Epidemiological studies concurred with a diminution in incidence [23-27]. Despite their prevention effects on cognitively healthy older adults, long-term use of these drugs are often accompanied by incommoding or even dangerous side effects. [28]. Therefore, alternative methods might be favored to target inflammation in individuals with MCI.

Mindfulness-based interventions (MBIs) are amongst the alternative methods that could be used to reduce inflammation in MCI. Mindfulness programs generally stem from the Mindfulness-Based Stress Reduction (MBSR) program of Jon Kabat-Zinn [29]. These include different types of meditation practices where individuals cultivate the ability to pay attention to the present moment in a non-judgmental way. MBIs are accessible and have limited negative side effects, as is the case of other psychosocial interventions bringing to consciousness the presence of negative experiences. A meta-analysis indicated a decrease of circulating levels of TNF-α following MBIs, an observation that was constant across different study protocols and populations [30]. Multiple studies also reported decreases of IL-6 following MBIs, although this effect might not be as generalized as TNF-α [30-34].

Despite a growing body of research highlighting MBIs’ effects on inflammation, the underlying mechanisms are still poorly understood [35]. It is recognized that MBIs reduce depressive symptoms in different populations [36, 37], including the elderly [38, 39]. This is of interest since the expression of inflammatory markers, including IL-6, were found to be higher in depressed elderly patients with diabetes and co-occurring MCI in comparison to elderly diabetics with depressive symptoms, but without MCI [40].

Heightened levels of IL-6 and TNF-α have also been involved in the emergence of depressive symptoms in major depressive disorder [41-45]. Furthermore, a reduction in depressive symptoms has been observed following NSAIDs administration [46], as well as an attenuation of circulating inflammatory activation [47]. In light of the association between depressive symptoms and circulating cytokine levels, it is possible that the antidepressant effects of MBIs may be due, at least in part, to their normalizing effect on the inflammatory process. This hypothesis is particularly interesting to investigate in individuals with MCI because this population often presents co-occurring depressive symptoms, which in turn adds to the inflammatory burden associated to this prodromal phase [40]. This heightened inflammation could explain why MCI individuals with concomitant depressive symptoms are at a higher risk of developing AD than individuals with MCI without mood symptoms [48]. To our knowledge, the effects of a mindfulness
intervention on circulating levels of IL-6 and TNF-α has not yet been investigated in individuals with MCI.

1.1 Aims and Hypotheses

The primary objective of this study was to examine the effects of a MBI on plasma levels of pro-inflammatory cytokines of MCI participants, with a particular focus on TNF-α and IL-6 because they have been implicated in AD progression [13, 14]. Given the potential of MBI to decrease inflammation [30], it is hypothesized that lower levels of TNF-α and IL-6 will be observed in participants of the MBI group.

The secondary objective aimed to investigate the possible association between variations in cytokine levels and depressive symptomatology in participants who were administered a MBI. It is hypothesized that such associations will be observed given the strong relation between peripheral inflammation and depressive symptoms exposed earlier.

2. Materials and Methods

The study was approved by the Research Ethics Board of the Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS-CN, approbation #2017-199) on August 21, 2017.

2.1 Participants

This study included 24 caucasian participants from both genders recruited through newspaper ads and medical references from Quebec City’s (Quebec, Canada) physicians. Participants had to be at least 55 years old and meet the core clinical MCI criteria of Albert et al. (2011). All participants with MCI suffered at least a mild episodic memory impairment (with or without impairment in other cognitive domains). Consent and information forms were signed by all participants before the start of the study. The exclusion criteria were as follows: 1) history of moderate or severe traumatic head injury; 2) history of stroke; 3) delirium in the last 6 months; 4) history of encephalitis or bacterial meningitis; 5) history of psychotic symptoms or manic episode; 6) electroconvulsive therapy in the last 12 months; 7) history of intracranial surgery; 8) cancer treatment in the last 12 months; 9) general anesthesia in the last 6 months, 10) neurodegenerative disorders (except suspected prodromal manifestations of AD); 11) untreated medical or metabolic conditions; 12) current major depressive disorder according to the diagnostic criteria of the DMS-5 (APA, 2013); 13) current substance abuse; 14) uncorrected vision or hearing problems; 15) recent experience with psychotherapy or cognitive restructuring that might impact cognition; 16) significant experience with meditation or other contemplative approaches.

2.2 Screening Evaluation

Trained research assistants screened participants and collected pre- and post-test efficacy measures. Potential candidates first underwent a screening evaluation at the CERVO Brain Research Centre (Quebec, Canada). A personal history interview as well as clinical and neuropsychological questionnaires and tests were administered to determine eligibility to the
study. The presence of an objective cognitive impairment was verified based on local (when available) normative data for standardized neuropsychological tests.

Clinical and neuropsychological batteries at screening evaluation. The Montreal Cognitive Assessment (MoCA) [49, 50] provided an appreciation of global cognitive functioning whereas subjective cognitive complaints were assessed with the Questionnaire de plainte cognitive (Subjective Complaints Questionnaire) [51], which is a semi-structured interview to predict the patient’s current ability in memory, orientation, language, activities and behavioural that relies on « yes » or « no » answers. Verbal episodic memory was evaluated with the Test de rappel libre/rappel indiqué à 16 items (RL/RI-16 - 16-item Free and Cued Recall) [52, 53] and semantic memory was assessed with the Pyramids and Palm Trees Test [54, 55]. Both visuoconstructive abilities and visual episodic memory were assessed using the Rey-Osterrieth Complex Figure Test [56-58]. Visuo-perception was evaluated with the size match subtest of the Birmingham Object Recognition Battery [59], whereas the Coding subtest from the WAIS-III [60] served as a measure of information processing speed. As for language, confrontation naming was assessed with the 15-item Boston Naming Test [61], and phonemic and semantic fluency, with T-N-P and Animal fluency, respectively [62, 63]. The D-KEFS version of the Stroop [64] was chosen to evaluate executive functioning. Under the assumption that circulating levels of cytokines covary with cognitive [18] and psychological features [40], most tests were meant to establish group equivalence at baseline on such variables. Furthermore, some of those tests were relevant to confirm the diagnostic of MCI.

2.3 Interventions

The eligible participants were randomly assigned to one of the two study interventions. Each intervention group was composed of 12 participants and interventions were held over a period of 8 weeks, with weekly sessions lasting 2.5 hours, including a 15 minutes break mid-session (see Table 1).

Mindfulness-based intervention (MBI). The MBI was elaborated by Larouche, Chouinard, and Goulet [65]. The program was based on Kabat-Zinn’s Mindfulness-Based Stress Reduction [29] and other sources [66-70]. The MBI was adapted to the needs and limitations of older adults with the help of recommendations from McBee [71] without compromising the essence and goals of leading mindfulness programs (ex: Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy). Adaptations included at-home meditative practices lasting 30 minutes rather than the usually recommended 40-45 minutes, execution of all forms of meditations in a seated position on a chair (with the exception of walking meditation), and simplified instructions with concrete examples relevant to the life of an aging person. Further information on the adaptations made to the standard MBI program can be found in Larouche, Chouinard, Morin-Alain, Hudon, & Goulet [72]. Group sessions comprised one or two guided meditation practices, group discussions, and psychoeducation about weekly mindfulness themes and stress management (see Table 1). Starting on week one, meditation practices were gradually introduced, starting with the body scan, mindful movements, meditation on senses (including mind sense), mindful walking, as well as mountains and loving-kindness meditations. Participants were also instructed to practice meditation at home for 30 minutes per day, six days a week, using vocal instructions on CDs, written instructions, as well as short texts related to weekly themes. In order to ensure adherence
or compliance to the intervention and to minimize attrition, participants were contacted by phone each week. The program was administered by its three developers, who possess the necessary credentials (available upon request).

Psychoeducation-based intervention (PBI). The PBI was developed by Parent, Larouche, Chouinard, and Hudon [73]. Participants were given psychoeducational classes on cognitive aging, each session being dedicated to a different topic (see Table 1). No reference was made to mindfulness techniques and attitudes or to strategies to improve cognition. A visually supported presentation was provided along with interactive activities consisting of group discussions, quizzes and smaller group interactions. Each participant received a binder with the written content of each session and room to take additional notes. The PBI was administered by Parent, who holds a master’s degree in psychoeducation, and the first author of the present study.

2.4 Pre- and Post-Tests

At the pretest, one week before the beginning of the trial, blood samples were collected by a licensed nurse whereas questionnaires and tests were administered. Given the influence of certain nutrients [74] and circadian rhythm [75] on cytokine production, blood samples were collected between 7:00 and 9:00 AM while participants were fasting. A breakfast was then offered before collection of the remaining measures. One week after completion of their respective 8-week intervention program, all participants took part in the post-test with the same efficacy measures as the pretest.

Primary efficacy measures. Plasma concentrations of IL-6 and TNF-α were used to determine the effects of MBI and PBI on circulating inflammatory activation. Blood samples were collected in heparin tubes and centrifuged within the next 30 minutes for 15 minutes at 200g and 4 °C. The plasma was then aliquoted and stored at -80 °C until subsequent analyses. Plasma concentrations of IL-6 and TNF-α were analysed in triplicates using flow cytometry BD Biosciences Cytometric Bead Array (CBA) Human Enhanced Sensitivity Kit (Catalog No. 561521; Becton, Dickinson and Company; BD Biosciences, San Diego, CA, USA). A FACS Aria II cytomter and the FCAP Array software were used to analyse the samples according to the manufacturer’s instructions (Becton, Dickinson and Company; BD Biosciences, San Diego, CA, USA). The sensitivity of the assay for each cytokine ranged from 274 to 200,000 fg/mL.

Secondary efficacy measure. Depression symptoms were determined with the full 30-item Geriatric Depression Scale, which demonstrates good reliability and validity (GDS) [76] and has been specifically validated with older adults with MCI [77]. A French version of the questionnaire was used [78]. For each of the 30 items, participants indicated whether or not the statement corresponded to how they felt in the last week. Of note, participants in this study did not meet diagnostic criteria of major depression according to the Diagnostic and Statistical Manual of Mental Disorders-IV, as evaluated with the Structured Interview for DSM disorders-I (SCID-I) [1, 79]. Depression symptoms, when present, were subclinical.

Moderator. Meditation practice at home was self-reported in a calendar. Participants noted the time they devoted to daily meditation as well as the type of meditation they practiced. This served to quantify adherence to the instructions and it allowed for assessment of the moderating effect of total practice time on plasma cytokine concentrations.
Table 1 Themes of MBI and PBI sessions.

| Session  | MBI                                | PBI                                          |
|----------|------------------------------------|----------------------------------------------|
| Session 1| Autopilot vs. mindfulness          | Normal vs. pathological cognitive aging and myths on AD |
| Session 2| Handling obstacles and supporting meditation practice efforts | Memory functions and normal decline in aging |
| Session 3| Wandering mind                      | Dementia continuum and the frequency of mood symptoms |
| Session 4| Acknowledging stress and its impact of one’s life to better manage it | AD risk factors and the influence of lifestyle habits on aging |
| Session 5| Reflecting on how one could live in increased acceptance of one’s situation | Medical follow-ups and discussions with physicians about cognitive concerns |
| Session 6| The role thoughts play in the maintenance of distress and stress | Relationships and discussions about cognitive decline with close relatives |
| Session 7| How to take better care of oneself | Everyday living with cognitive decline and coping with difficulties |
| Session 8| Sustaining a meditation practice beyond the program | What to do next with all the new knowledge participants acquired in the program |

Note. AD: Alzheimer disease; MBI: Mindfulness-based intervention; PBI: Psychoeducation-based intervention.

2.5 Statistical Analyses

Preliminary analyses. Data analyses were performed with the Statistical Package for the Social Sciences (SPSS, version 20) with a significance level set at \( p < .05 \). Variables were tested for normality of distribution, homogeneity of variance, and randomness of missing data distribution with the Shapiro-Wilk’s, Levene’s, and Little’s Missing Completely at Random (MCAR) statistical tests. Pre-intervention group equivalence on sociodemographic and clinical variables was verified using Student’s t tests for independent samples on continuous variables (i.e., education, Montreal Cognitive Assessment, and age) and a Chi-Square test for the nominal variable (i.e., sex). Since data relative to levels of cytokines were not normally distributed, Mann-Whitney U tests were used to achieve pre-intervention between group comparisons. Furthermore, Spearman correlations were calculated between levels of cytokines and the sociodemographic and clinical variables in order to add them as covariates in the subsequent mixed linear model, if necessary.

Efficacy analyses. A two factors (Intervention and Time) linear mixed model was carried out to determine differences between the two interventions groups (MBI and PBI) at the two-time repeated within group measures (pre- and post-intervention) for plasma levels of cytokines and scores on the GDS. For exploratory purposes and given the higher risk of AD progression with higher plasma levels of the two cytokines analysed [13, 14], each intervention group was split in
two based on baseline median plasma levels (0.08 pg/mL for TNF-α and 1.25 pg/mL for IL-6) to include this factor in the model. Cohen d’s were used as indicators of interaction effect sizes [80, 81] and partial eta squares (ηp²) were used as indicators of fixed factors’ effect sizes [82]. Spearman correlations were calculated between scores’ differences (deltas) for the two time points on the GDS and for the plasma levels of cytokines to determine potential relationships between cytokine changes and depression improvements resulting from the interventions.

Complementary analyses. To take into account the potential impact of meditation practice at home on the levels of cytokines post-intervention, MBI participants were divided into two subgroups according to the total amount of time dedicated to at-home meditation for the entire program (MBI+: total time above the median of 1.103 minutes; MBI-: total time below the median). As a comparative, the recommended time of at-home practice was equivalent to 1.440 minutes. These two groups were then compared for plasma levels of cytokines at pre- and post-intervention in a two-factor linear mixed model. Cohen’s d and partial eta squares (ηp²) were also calculated.

3. Results

3.1 Participants’ Characteristics

Of the 24 participants included, 23 (11 in MBI and 12 in PBI) attended at least one intervention session and thus were included in the characteristic and correlation analysis for pre-intervention data. Of these 23 participants, 21 (9 in MBI and 12 in PBI) attended at least five sessions which is more than 50% of the total number of sessions and thus were included in the efficacy and complementary analyses following an “as treated” protocol [83]. Characteristics of participants on demographic and cognitive variables at pre-intervention are presented in Table 2, section A. Both interventions groups were equivalent on all variables, except for the second free recall on the verbal episodic memory test (RL/RI-16). Results for this second free recall on the RL/RI-16 were thus correlated to the efficacy measures at pre-intervention, IL-6 plasma levels (rₛ[21] = -0.041, p = 0.854), TNF-α plasma levels (rₛ[21] = -0.0231, p = 0.289) and scores on the GDS (rₛ[21] = 0.425, p = 0.043). Only the latter was significant.

Table 2 Means (SD) and significance levels for all variables at pretest according to the intervention group.

A) Sociodemographic and cognitive variables.

| Variables                        | MBI (n=11) | PBI (n=12) | T value | df  | P    |
|----------------------------------|------------|------------|---------|-----|------|
| **Sociodemographics**            |            |            |         |     |      |
| Sex                              | 5m/6f      | 7m/5f      | 0.38 (x²) | 1   | 0.68 |
| Age                              | 72 (5.37)  | 69 (6.23)  | -1.10   | 21  | 0.28 |
| Years of education               | 14 (4.06)  | 15 (2.16)  | 0.35    | 21  | 0.74 |
| Global cognitive functioning and complaints | | | | |
| Global cognitive functioning; MoCA (/30) | 24 (2.86) | 25 (1.00) | -0.55   | 21  | 0.59 |
| Cognitive complaints; CCQ (/10) | 6 (2.83) | 5 (2.86) | -0.61 | 21 0.55 |
|--------------------------------|---------|---------|-------|-------|
| **Verbal episodic memory; 16 word free and cued recall** | | | | |
| Free recall 1 (Z score) | -1.34 (0.84) | -0.64 (0.95) | 1.87 | 21 0.08 |
| Free recall 2 (Z score) | -1.69 (0.94) | -0.37 (1.00) | 3.24 | 21 0.00* |
| Free recall 3 (Z score) | -1.47 (0.84) | -1.20 (0.69) | 0.84 | 21 0.41 |
| Delayed free recall (Z score) | -1.60 (1.15) | -1.17 (0.92) | 0.98 | 21 0.34 |
| Visual episodic memory; Rey figure copy task (immediate recall) (Z score) | 0.47 (1.70) | -0.65 (2.02) | -1.42 | 21 0.17 |
| Semantic memory; PPTT (% normal) | 100% | 100% | - | - | - |
| **Verbal fluency** | | | | |
| Lexical (T-N-P task) (Z score) | -0.41 (0.85) | -0.55 (0.73) | -0.41 | 21 0.69 |
| Semantic (Animal fluency) (Z score) | -0.30 (0.84) | -0.24 (1.02) | 0.14 | 21 0.87 |
| **Confrontation naming (BNT, 15 items)** | | | | |
| Spontaneous (Z score) | 0.10 (0.69) | -0.30 (0.88) | -1.20 | 21 0.25 |
| Total (Z score) | 0.25 (0.63) | -0.19 (0.79) | -1.47 | 21 0.16 |
| **Visuoperception and visuoconstruction** | | | | |
| Construction (Rey Figure copy) (Z score) | -0.63 (1.16) | -1.28 (1.18) | -1.34 | 21 0.19 |
| Perception (BORB circles) (Z score) | -0.28 (0.97) | -0.54 (1.32) | -0.55 | 21 0.59 |
| **Executive functions (D-KEFS Stroop)** | | | | |
| Inhibition time (Z score) | -0.33 (1.20) | -0.14 (1.33) | 0.37 | 21 0.72 |
| Switching time (Z score) | 0.17 (1.30) | -0.39 (1.39) | -0.96 | 20 0.35 |
| Inhibition errors (Z score) | -0.09 (1.00) | 0.20 (0.69) | 0.80 | 21 0.43 |
| Switching errors (Z score) | -0.23 (1.09) | -0.36 (0.99) | -0.28 | 20 0.78 |
| Processing speed (Coding from WAIS-III) (Z score) | 0.18 (0.87) | -0.09 (0.77) | -0.78 | 21 0.45 |
B) Primary and secondary efficacy measures.

| Blood levels of cytokines (pg/mL) | IL-6  | TNF-α  |
|----------------------------------|-------|--------|
|                                  | 2.56 (2.48) | 0.11 (0.10) |
|                                  | 2.92 (5.59) | 0.06 (0.05) |
|                                  | -      | -      |
|                                  | 0.260 (U)  | 0.295 (U)  |

| Depressive symptoms | GDS (/30) | 10 (6.72) | 8 (3.59) | 0.95 | 21 | 0.36 |
|---------------------|-----------|-----------|----------|------|----|------|

Note. Result for plasma levels are in picograms per milliliter (pg/mL). PBI: Psychoeducation-based intervention; MBI: Mindfulness-based intervention; MoCA: Montreal Cognitive Assessment; BORB: Birmingham Object Recognition Battery; CCQ: Cognitive Complaint Questionnaire; D-KEFS: Delis-Kaplan Executive Function System; PPTT: Pyramids and Palm Trees Test; BNT: Boston Naming Test; WAIS: Weschler Adult Intelligence Scale. GDS: Geriatric Depression Scale; IL-6: Interleukin-6; TNF-α: Tumor Necrosis Factor Alpha; n: number of participants; SD= Standard deviation; p = significance level; df = degrees of freedom; m = males; f= females

a Significant level corresponding to Chi squared test
b Significant level corresponding to U Mann-Whitney test

*p <0.05

3.2 Preliminary Measures

Groups were equivalent at pre-intervention on primary and secondary efficacy measures (see Table 2, section B). Furthermore, there were no significant correlations between levels of cytokines at pre-intervention and the variables sex, age, education, and global cognitive functioning (see Table 3). One outlier in the PBI group was removed given the pronounced variation between post and pre-test levels (drop of 16.26 pg/mL), which differed from the rest of the group (Z=-3.16). As for TNF-α levels, 17.4% of the samples failed to reach acceptable detection range. After confirmation that these data were missing completely at random (χ2 = 0.00, p = 1.00), they were replaced with generated data below the detection range using the maximum likelihood model [84].

Table 3 Spearman correlations between demographic, clinical, and cognitive screening characteristics and blood levels of cytokines (pg/mL) for all participants at pre-intervention (N= 23).

|        | Age  | Years of education | Sex   | MoCA (/30) | GDS (/30) |
|--------|------|--------------------|-------|------------|-----------|
| IL-6   | -0.062 | -0.133            | -0.236 | -0.137     | -0.073    |
| TNF-α  | 0.005  | -0.069            | -0.098 | 0.096      | -0.299    |

GDS: Geriatric Depression Scale; MoCA: Montreal Cognitive Assessment; IL-6: Interleukin-6; TNF-α: Tumor Necrosis Factor alpha
3.3 Primary Efficacy Measures; Plasma Levels of Cytokines

TNF-α. There was no overall effect of MBI or PBI on plasma levels of TNF-α (see Figure 1).

![Figure 1](Plasma levels (pg/mL) of TNF-α in MBI (n= 9) and PBI (n= 12) groups at pre- and post-test. Pre: pretest; Post: post-test; MBI: Mindfulness-based intervention; PBI: Psychoeducation-based intervention; pg/mL: Picogram per milliliter.

The Time ($p = 0.890, \eta_p^2 =0.00$) and Intervention ($p = 0.204, \eta_p^2 = 0.083$) factors as well as the Time x Intervention interaction ($p = 0.127, d = 0.036$) were not significant. However, when each of the intervention group was divided according to baseline levels of TNF-α, visual inspection of Figure 2 suggested that MBI participants with higher initial levels of TNF-α had reduced levels of this cytokine after the intervention. The use of a three-factor linear mixed model confirmed that the Time, Intervention, and Initial plasma level interaction was not statistically significant ($p = 0.252$) but was coupled with a moderate effect size ($d = 0.622$). Pairwise comparisons showed that plasma TNF-α levels did not significantly change between the two time measures for the MBI-low initial level group ($p = 0.330$), the PBI-low initial level group ($p = 0.168$), or the PBI-High initial level group ($p = 0.682$) and that a non-significant trend for the cytokine to decrease in the MBI-High initial level group was observed (MBI-High; $p = 0.068$). This tendency was coupled with a moderate effect size ($d = 0.500$) as compared to the MBI group as a whole ($d = 0.195$).
**Figure 2** Plasma levels (pg/mL) of TNF-α in MBI (n = 9, high = 5, low = 4) and PBI (n = 12, high = 4, low = 8) groups at pre- and post-test according to initial levels. **Pre:** pretest; **Post:** post-test; **MBI-High:** Mindfulness-based intervention, high initial plasma level; **MBI-Low:** Mindfulness-based intervention, low initial plasma level; **PBI-High:** Psychoeducation-based intervention, high initial plasma level; **PBI-Low:** Psychoeducation-based intervention, low initial level **pg/mL:** Picogram per milliliter.

IL-6. Visually, IL-6 plasma levels seemed to increase in the MBI group following the intervention, whereas levels in the PBI group did not appear to differ from the pretest to post-test (see Figure 3).

**Figure 3** Plasma levels (pg/mL) of IL-6 in MBI (n = 9) and PBI (n = 11) groups at pre- and post-test. **Pre:** pretest; **Post:** post-test; **MBI:** Mindfulness-based intervention; **PBI:** Psychoeducation-based intervention; **pg/mL:** Picogram per milliliter.
The factors Time ($p = 0.110$, $\eta_p^2 = 0.135$) and Intervention ($p = 0.157$, $\eta_p^2 = 0.108$) were not significant. Likewise, the Time x Intervention interaction was not significant ($p=0.128$) but was associated with a moderate effect size ($d=0.54$). Pairwise comparisons revealed a significant increase of plasma IL-6 levels from pretest to post-test in the MBI group ($p = 0.04$), with no significant cytokine variation in the PBI group ($p = 0.952$). The split of participants according to plasma IL-6 levels at pre-intervention did not yield a significant Time, Intervention, and Initial plasma level interaction ($p = 0.884$, $d = 0.351$) (see Figure 4). No particular tendency worthy of further analyses was observed on the basis of this categorization.

**Figure 4** Plasma levels (pg/mL) of IL-6 in MBI (n = 8, high = 5, low = 3) and PBI (n = 10, high = 4, low = 6) groups at pre- and post-test according to initial levels. **Pre**: pretest; **Post**: post-test; **MBI-High**: Mindfulness-based intervention, high initial plasma level; **MBI-Low**: Mindfulness-based intervention, low initial plasma level; **PBI-High**: Psychoeducation-based intervention, high initial plasma level; **PBI-Low**: Psychoeducation-based intervention, low initial level **pg/mL**: Picogram per milliliter.

### 3.4 Secondary Efficacy Measures; Depressive Symptoms

Following each intervention, GDS scores decreased on average by about two points. The mean score in the MBI group went from $11.3 \pm 1.7$ to $9.8 \pm 2.1$ and from $7.8 \pm 1.5$ to $5.1 \pm 1.8$ in the PBI group. However, the Time ($p = 0.09$, $\eta_p^2 = 0.144$) and Intervention ($p = 0.548$, $\eta_p^2 = 0.150$) factors were not statistically significant, and no Time x Intervention interaction was found ($p = 0.626$, $d = 0.224$). GDS scores were not correlated with either IL-6 ($r_s [21] = -0.073$, $p = 0.741$) or TNF-α ($r_s [21] = -0.299$, $p = 0.165$) levels at pre-intervention. No significant correlations were obtained between GDS score differences (deltas) at the two measure points and the levels of IL-6 ($r_s [18] = 0.130$, $p = 0.586$) and TNF-α ($r_s [19] = -0.138$, $p = 0.550$).
3.5 Complementary Measures; Amount of Meditation Practice

Effect on TNF-α levels. No significant effect of meditation practice on TNF-α was observed in MBI participants, although a non-significant trend towards a decrease in TNF-α levels at post-intervention was observed in participants with a higher meditative practice ($d = 0.405$), with no effect noted for participants who practiced less ($d = 0.066$) (see Figure 5). The effect of Time alone on TNF-α levels was not significant ($p = 0.425$, $\eta^2_p = 0.101$) and no significant Time by Amount of meditation practice interaction was observed ($p = 0.280$), but the effect size was moderate ($d = -0.471$).

![Figure 5](image)

**Figure 5** Plasma levels of TNF-α at pre and post-test for MBI participants according to amount of meditation practice. **MBI +**: Above median meditation practice subgroup (n= 4); **MBI -**: Below median meditation practice subgroup (n= 4).

Effect on IL-6 levels. A non-significant trend towards an increase in IL-6 levels post-MBI was more marked for participants who devoted more time to meditation practice relative to those who meditated below the median. Indeed, IL-6 concentrations of individuals with a higher meditation practice increased by 1.710 pg/mL ± 0.880, $d = 0.631$, whereas IL-6 concentrations of individuals with a lower meditation practice increased by 0.784 pg/mL ± 0.880, $d = 0.377$. The factor Time was not significant ($p = 0.206$, $\eta^2_p = 0.251$). The Time x Meditation practice interaction was not significant either ($p= 0.618$), and the effect size was low to moderate ($d = 0.254$).

4. Discussion

The primary objective of this study was to examine the effects of MBI on circulating levels of pro-inflammatory cytokines of MCI participants, with a particular focus on plasma levels of TNF-α and IL-6. As a secondary objective, the study aimed at investigating the possible associations between variations in cytokine levels and depressive symptomatology in the MBI group, which
could have been suggestive of inflammatory-driven mechanisms leading to mood improvements in these participants.

Although no robust effects of the study interventions on plasma levels of pro-inflammatory cytokines were observed, some observations appeared to be in line with a priori hypotheses and previous literature. In particular, TNF-α levels tended to decrease post-MBI but only in participants who had higher levels of the cytokine before the intervention, suggesting that mindfulness interventions could be more impactful in individuals with higher baseline inflammatory states. This was specific to MBI since PBI participants did not show such a tendency. Interestingly, TNF-α levels also tended to decrease in those participants who practice more meditation at home, an aspect that future studies should investigate. This inclination towards a decrease in TNF-α for the MBI group is consistent with previous findings. Mindfulness interventions have been associated with decreased circulating levels of TNF-α, an effect that was generalised across study designs (population of interest, type of mindfulness practice, study protocol, etc.) [30]. In line with the view that mindfulness effect could be dependent on the initial inflammatory state of the body, antidepressant effects of infliximab, a TNF-α antagonist drug, were only observed in participants with higher initial level of TNF-α [85]. Alternatively, in this study, the trend towards decrease of TNF-α levels following MBI could be due to the fact that several MCI participants were actually in the prodromal phase of AD. Indeed, as mentioned earlier, higher circulating levels of TNF-α, as compared to healthy controls, were associated with a higher risk of progression from MCI to AD [86]. Some authors listed TNF-α amongst the most predictive biomarkers of AD [87]. Longitudinal studies will be necessary to explore the hypothesis of a decrease in TNF-α specific to MCI individuals having higher initial levels of this cytokine, and thus being at higher risk of developing AD.

In contrast with our initial hypotheses, a trend towards heightened plasma IL-6 was observed post-MBI, which appeared to be more pronounced in participants who devoted a higher amount of meditation practice at home. Unlike TNF-α that displays consistent patterns following mindfulness interventions, literature reviews and meta-analysis did not report overall decreases or increases for IL-6 following mindfulness interventions, which could be due to this cytokine’s sensitivity to variations in clinical trial characteristics (study protocol, population studied, etc.). Nevertheless, some studies did report a rise of IL-6 following mindfulness interventions in populations such as breast cancer patients [88] and healthy adults [89], and this rise was considered beneficial. In the context of AD, however, the overall assumption regarding peripheral levels of IL-6 is that of a gradual augmentation with the progression of the disease [13, 90]. The specific role of IL-6 in AD has yet to be determined, but it has been suggested that its secretion could contribute to a damageable pro-inflammatory response involved in AD pathogenesis [11]. In this frameset, an intervention that increases levels of IL-6 in MCI participants could thus be considered detrimental. However, the evolution of IL-6 in AD could be more complex and sensitive to the progression of the disease over time. A multicentre study carried out by Cao and collaborators [91] revealed lower plasma levels for this cytokine in MCI participants who later progressed to MA within two to four years compared to participants who remained stable, suggesting that a failure of the immune system to generate an appropriate response at a crucial time could promote the installation of AD pathology. In line with this view, the longitudinal PREVENT-AD study reported the decrease of six cerebrospinal fluid inflammatory markers with the first signs of Aβ and Tau pathology, followed by a strong sustainable increase [92], adding support
to the hypothesis of an impaired inflammatory response in the early stages of AD favouring the
evolution of the pathology. Similarly, an inverse association between chronically raised C reactive
protein (a pro-inflammatory mediator) and cerebral amyloid beta (Aβ) has been reported in non-
demented elderly individuals reporting subjective memory complaints [93], suggesting that certain
inflammatory processes could be beneficial at early stages of AD as the immune system attempts
to combat Aβ pathology. According to this hypothesis, a strong immune response might be
necessary for defending the brain and body against the formation of Aβ plaques and other
pathophysiological processes in the early stages of AD. Therefore, the trend towards an increment
in IL-6 following MBI observed in this study, although nonsignificant could indicate a useful pro-
inflammatory response since its timing is opportune (MCI stage), a hypothesis that should be
addressed in longitudinal studies.

Contrary to our hypothesis, plasma cytokine changes in the MBI group, although non-significant,
were not associated with variations in depressive symptomatology. Depressive symptomatology is
dependent on a plethora of environmental factors. There is a lot of heterogeneity between
participants in this regard. In our understanding, an elevated level of circulating cytokines is not
causative of the depressive symptomatology but covary with it and contributes in the
perpetuation of those symptoms. A larger study is necessary to explore this association. With
authors reporting an association between stress reduction and inflammation variations following a
compassion meditation practice [94], this possible association was also briefly investigated in this
study. Indeed, this project being embedded in a larger one, we were able to conduct exploratory
analysis with perceived anxiety symptoms of participants using the GAI (Geriatric Anxiety
Inventory). For methodology on this matter see Chouinard, Larouche, Audet, Hudon, & Goulet [95].
No significant association was found between the GAI scores and IL-6 (r [21] = -0.089, p= 0.685) or
TNF-α (r [21] = -0.262, p= 0.227) levels at pretest. Also, no significant correlations were found
between score differences at the two measure points of the GAI and the levels of IL-6 (r [18] = -
0.067, p= 0.780) and TNF-α (r [19] = -0.074, p= 0.750). This absence of associations between
variations of psychological and cytokine measures might indicate that the effect of mindfulness on
both of these outcomes does not stem from a common action mechanism, but rather from
independent ones. It is also possible that the variation on depressive symptoms was not important
even to correlate with other pre-post variations in cytokine plasma levels. Participants had mild
depressive symptoms [96] on average pre-intervention. Although there was a decrease towards a
normal range of symptoms post-intervention in both groups, the decrease was not statistically
significant. Perhaps a more severe depressive symptomatology at baseline would have been more
favorable statistically, but this is not what the present sampling method yielded. As well, groups
differed on the second free recall of the RL/RI-16, which positively correlated to GDS scores. This
could have exerted an influence on the results, although this positive correlation is surprising
given that depressive symptoms usually have a negative influence on memory performances,
especially in the elderly [97]. One other explanation could be that the initial levels of TNF-α were
not high enough to observe a diminution in depressive symptomatology, as was observed in the
infliximab trial by Raison and collaborators [85]. Further studies are necessary to test these
hypotheses, with a larger sample size to conduct moderation analysis, a more robust design to
investigate the complex relations between physiological and psychological measures.

This study has limitations. First, due to its exploratory nature, the number of participants was
limited. Nevertheless, the tendencies observed, although they did not reach significance, could
guide future research on the physiological effects of mindfulness interventions. Second, the loss of TNF-α data calls for caution regarding the interpretations of the variation of this cytokine following the MBI and PBI. Although the present results are interpreted in light of an active control group with participants having similar neuropsychological, clinical, demographic, and physiological profiles at pre-intervention, thus controlling for a number of confounding variables, further studies must be conducted to confirm the tendencies observed. Nevertheless, the use of the PBI group has permitted the distinction of tendencies specific to the MBI, such as the trends towards IL-6 elevations and TNF-α reductions that were only observed for this intervention. Furthermore, there are possible meditation practice effects associated with both cytokines, which could further reinforce the notion of a MBI-specific effect on inflammation profiles in participants with MCI.

5. Conclusions

To our knowledge, this is the first study to investigate the effects of a MBI compared to an active control condition on the circulating inflammatory levels of pro-inflammatory cytokines in participants with MCI. These preliminary findings suggest tendencies for plasma levels of IL-6 and TNF-α that were specific to MBI. This is of importance since both cytokines have known implications in the pathophysiology of AD. Therefore, interventions that could modify the peripheral inflammation profile of people at risk for AD could potentially limit or alter the progression of the disease. MBIs show promise since they are easily implemented, affordable, and may have beneficial physiological effects on modifiable risk factors of AD.

This exploratory study opens the way to further investigations regarding this preventive strategy. Future studies might want to include a more sensitive detection kit and a larger sample of participants in order to replicate these results with more certainty. Furthermore, additional participants would allow for moderation analysis, which would permit further investigation of the action mechanism behind MBIs. Finally, given the interesting variations on cytokine levels with the progression of AD, a longitudinal study could be interesting to assess the long-term effects of MBIs on inflammatory markers of elderly with MCI, especially in relation to the evolution of their condition.

Acknowledgments

The authors wish to thank the Cell Sorting Platform at CERVO Brain Research Centre and Yvon Chagnon, Associate Professor at the Faculty of Medicine of Université Laval, for their contribution in this project.

Author Contributions

Valérie Morin-Alain contributed to the elaboration of research questions, literature review, recruitment and data collection, administration of the PBI, data entry, analysis and interpretations and the writing of the article.

Eddy Larouche contributed to the elaboration of the study protocol, recruitment and data collection, analysis, creation of both intervention manuals and administration of the MBI.

Anne-Marie Chouinard contributed to the elaboration of the study protocol, recruitment and data collection and creation of both intervention manuals.
Marie-Claude Audet supervised the scientific methods behind the obtention of the physiological data and contributed to the interpretations of results and the writing of the article.

Sonia Goulet contributed to the supervision of the scientific method, elaboration of the study protocol, creation of intervention manual and administration of the MBI, results interpretations and writing of the article.

Louis-Simon Rousseau contributed to the interpretations of results and the writing of the article.

Carol Hudon contributed to the supervision of the scientific method, elaboration of the study protocol, results interpretations and writing of the article.

**Funding**

This research was funded by the Quebec Research Network on Aging, the Caisse Desjardins de Québec, and the Quebec’s Alzheimer Society.

**Competing Interests**

The authors have declared that no competing interests exist.

**References**

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA: American Psychiatric Association Publishing; 2013.
2. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011; 10: 819-828.
3. Gauthier S, Wu L, Rosa-Neto P, Jia J. Prevention strategies for Alzheimer's disease. Transl Neurodegener. 2012; 1: 13.
4. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, et al. A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. Alzheimers Dement. 2008; 4: 156-163.
5. Mitchell S, Ridley SH, Sancho RM, Norton M. The future of dementia risk reduction research: Barriers and solutions. J Public Health (Oxf). 2017; 39: e275-e281.
6. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: An analysis of population-based data. Lancet Neurol. 2014; 13: 788-794.
7. World Health Organization. Dementia: A public health priority. 2012. Available from: http://www.who.int.
8. Hurley LL, Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotox Res. 2013; 23: 131-144.
9. Okun E, Chen X, Basta M, Mattson MP. Roles of Innate Immunity and Inflammation in the Aging Brain. Inflammation, lifestyle, and chronic disease the silent link. Boca Raton, FL: CRC Press; 2012.
10. McEwen BS. Physiology and neurobiology of stress and adaptation: Central role of the brain. Physiol Rev. 2007; 87: 873-904.
11. Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S. Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis. J Neurol Sci. 2017; 376: 242-254.
12. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007; 7: 161-167.

13. Lai KSP, Liu CS, Rau A, Lanctot KL, Kohler CA, Pakosh M, et al. Peripheral inflammatory markers in Alzheimer's disease: A systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry. 2017; 88: 876-882.

14. Zheng C, Zhou XW, Wang JZ. The dual roles of cytokines in Alzheimer's disease: Update on interleukins, TNF-alpha, TGF-beta and IFN-gamma. Transl Neurodegener. 2016; 5: 7.

15. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett. 2008; 117: 198-202.

16. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al. Inflammatory proteins in plasma and the risk of dementia: The rotterdam study. Arch Neurol. 2004; 61: 668-672.

17. Guerreiro RJ, Santana I, Bras JM, Santiago B, Paiva A, Oliveira C. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener Dis. 2007; 4: 406-412.

18. Zhao SJ, Guo CN, Wang MQ, Chen WJ, Zhao YB. Serum levels of inflammation factors and cognitive performance in amnestic mild cognitive impairment: A Chinese clinical study. Cytokine. 2012; 57: 221-225.

19. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009; 119: 252-265.

20. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 270-279.

21. Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci. 2010; 2.

22. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011; 7: 402-411.

23. Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer's disease: Evidence for NSAIDs and novel therapeutics. Expert Rev Neurother. 2017; 17: 17-32.

24. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. BMJ. 2003; 327: 128.

25. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997; 48: 626-632.

26. in 't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001; 345: 1515-1521.

27. Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer's disease: An updated systematic review and meta-analysis. J Alzheimers Dis. 2015; 44: 385-396.
28. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018; 9: 143-150.

29. Kabat-Zinn J. Full catastrophe living: Using the wisdom of your body and mind to face stress, pain, and illness. New York: Dell Publishing; 1990.

30. Pascoe MC, Thompson DR, Jenkins ZM, Ski CF. Mindfulness mediates the physiological markers of stress: Systematic review and meta-analysis. J Psychiatr Res. 2017; 95: 156-178.

31. Bower JE, Irwin MR. Mind-body therapies and control of inflammatory biology: A descriptive review. Brain Behav Immun. 2016; 51: 1-11.

32. Bower JE, Crosswell AD, Stanton AL, Crespi CM, Winston D, Arevalo J, et al. Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial. Cancer. 2015; 121: 1231-1240.

33. Creswell JD, Taren AA, Lindsay EK, Greco CM, Gianaros PJ, Fairgrieve A, et al. Alterations in resting-state functional connectivity link mindfulness meditation with reduced interleukin-6: A randomized controlled trial. Biol Psychiatry. 2016; 80: 53-61.

34. Tomfohr LM, Pung MA, Mills PJ, Edwards K. Trait mindfulness is associated with blood pressure and interleukin-6: Exploring interactions among subscales of the Five Facet Mindfulness Questionnaire to better understand relationships between mindfulness and health. J Behav Med. 2015; 38: 28-38.

35. Alsubaie M, Abbott R, Dunn B, Dickens C, Keil TF, Henley W, et al. Mechanisms of action in mindfulness-based cognitive therapy (MBCT) and mindfulness-based stress reduction (MBSR) in people with physical and/or psychological conditions: A systematic review. Clin Psychol Rev. 2017; 55: 74-91.

36. Goldberg SB, Tucker RP, Greene PA, Davidson RJ, Wampold BE, Kearney DJ, et al. Mindfulness-based interventions for psychiatric disorders: A systematic review and meta-analysis. Clin Psychol Rev. 2018; 59: 52-60.

37. Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. J Consult Clin Psychol. 2010; 78: 169-183.

38. Geiger PJ, Boggero IA, Brake CA, Caldera CA, Combs HL, Peters JR, et al. Mindfulness-based interventions for older adults: A review of the effects on physical and emotional well-being. Mindfulness (N Y). 2016; 7: 296-307.

39. Khoury B, Lecomte T, Fortin G, Masse M, Therien P, Bouchard V, et al. Mindfulness-based therapy: A comprehensive meta-analysis. Clin Psychol Rev. 2013; 33: 763-771.

40. Gorska-Ciebiada M, Saryusz-Wolska M, Borkowska A, Ciebiada M, Loba J. Serum levels of inflammatory markers in depressed elderly patients with diabetes and mild cognitive impairment. PLoS One. 2015; 10: e0120433.

41. Frodl T, Amico F. Is there an association between peripheral immune markers and structural/functional neuroimaging findings? Prog Neuro-Psychoph. 2014; 48: 295-303.

42. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012; 36: 764-785.

43. Lichtblau N, Schmidt FM, Schumann R, Kirkby KC, Himmerich H. Cytokines as biomarkers in depressive disorder: Current standing and prospects. Intern Rev Psychiat (Abingdon Engl). 2013; 25: 592-603.
44. Miller AH. Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface. Brain Behav Immun. 2009; 23: 149-158.

45. Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord. 2014; 169: 15-20.

46. Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014; 71: 1381-1391.

47. Furtado M, Katzman MA. Examining the role of neuroinflammation in major depression. Psychiat Res. 2015; 229: 27-36.

48. Hermida AP, McDonald WM, Steenland K, Levey A. The association between late-life depression, mild cognitive impairment and dementia: Is inflammation the missing link? Expert Rev Neurother. 2012; 12: 1339-1350.

49. Larouche E, Tremblay MP, Potvin O, Laforest S, Bergeron D, Laforce R, et al. Normative data for the montreal cognitive assessment in middle-aged and elderly Quebec-French people. Arch Clin Neuropsychol. 2016.

50. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53: 695-699.

51. Thomas-antierion C, Ribas C, Honore-masson S, Million J, Laurent B. Evaluation de la plainte cognitive de patients Alzheimer, de sujets MCI, anxiodépressifs et de témoins avec le QPC (Questionnaire de Plante Cognitive). NPG Neurologie - Psychiatrie - Gériatrie. 2004; 4: 30-34.

52. Van der Linden M. L'épreuve de rappel libre / rappel indicé à 16 items (RL/RI-16). Marseille; 2004. 25-47. p.

53. Dion M, Potvin O, Belleville S, Ferland G, Renaud M, Bherer L, et al. Normative data for the pyramids and palm trees test in the Quebec-French population. Arch Clin Neuropsychol. 2010; 25: 212-217.

54. Riddoch MJ, Humphreys GW. Birmingham object recognition battery: Lawrence Erlbaum Associates; 1993.

55. Wechsler D. WMS-III: Wechsler memory scale administration and scoring manual. Psychological Corporation; 1997.
61. Calero MD, Arnedo ML, Navarro E, Ruiz-Pedrosa M, Carnero C. Usefulness of a 15-item version of the Boston Naming Test in neuropsychological assessment of low-educational elders with dementia. J Gerontol B Psychol Sci Soc Sci. 2002; 57: P187-191.

62. Consortium des Universités de Montréal et de McGill. Manuel de l'Examen Neuropsychologique. Montréal : Données non publiées; 1996.

63. St-Hilaire A, Hudon C, Vallet GT, Bherer L, Lussier M, Gagnon JF, et al. Normative data for phonemic and semantic verbal fluency test in the adult French-Quebec population and validation study in Alzheimer's disease and depression. Clin Neuropsychol. 2016; 30: 1126-1150.

64. Delis DC, Kaplan E, Kramer JH. The Delis-Kaplan Executive Function System manual. San Antonio, TX: The Psychological Corporation; 2001.

65. Larouche E, Goulet S, Chouinard A-M. Manuel d’intervention: Intervention basée sur la pleine conscience pour adultes âgés présentant un trouble cognitif léger. Université Laval de Québec: École de psychologie; 2015.

66. Bartley T. Mindfulness-based cognitive therapy for cancer. John Wiley & Sons; 2011.

67. Carlson LE, Specia M. Mindfulness-based cancer recovery: A step-by-step MBSR approach to help you cope with treatment and reclaim your life. Oakville, CA: New Harbinger; 2010.

68. Fournier C. Manuel d’intervention: Rencontrer le stress avec la présence attentive. Unpublished manuscript. 2011.

69. Monestès J. L, Villate M. La thérapie d’acceptation et d’engagement ACT. Paris, France: Elsevier-Masson; 2011.

70. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression. Guilford Press; 2012.

71. McBee L. Mindfulness-based elder care: A CAM model for frail elders and their caregivers. New York: Springer Publishing Company; 2008.

72. Larouche E, Chouinard A-M, Morin-Alain V, Hudon C, Goulet S. Adaptation d’une intervention basée sur la pleine conscience à des personnes âgées ayant un trouble cognitif léger. Pleine conscience et intervention clinique. Québec: Les Presses de l’Université Laval; 2018. p. 239-256.

73. Parent A, Larouche E, Chouinard A-M, Hudon C. Manuel d’intervention: Intervention de psychoéducation pour les adultes âgés présentant un trouble cognitif léger. Québec: Université Laval; 2015.

74. Galland L. Diet and inflammation. Nutr Clin Pract. 2010; 25: 634-640.

75. Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci. 2010; 1193: 48-59.

76. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res. 1982; 17: 37-49.

77. Debruyne H, Van Buggenhout M, Le Bastard N, Aries M, Audenaert K, De Deyn PP, et al. Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? Int J Geriatr Psychiatr. 2009; 24: 556-562.

78. Bourque P, Blanchard L, Vézina J. Étude psychométrique de l’Échelle de dépression gériatrique. Canadian J Aging. 2010; 9: 348-355.
79. First MB, Williams JBW, Spitzer RL, Gibbon M. Structured clinical interview for DSM-IV-TR Axis I Disorders, Clinical Trials version (SCID-CT). New York State Psychiatric Institute. New York: Biometrics Research; 2007.
80. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum; 1988.
81. Feingold A. A regression framework for effect size assessments in longitudinal modeling of group differences. Rev Gen Psychol. 2013; 17: 111-121.
82. Bakeman R. Recommended effect size statistics for repeated measures designs. Behav Res Methods. 2005; 37: 379-384.
83. Armijo-Olivo S, Warren S, Magee D. Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: A review. Phys Ther Rev. 2013; 14: 36-49.
84. Enders CK. Applied missing data analysis. New York & London: Guilford press; 2010.
85. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013; 70: 31-41.
86. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003; 74: 1200-1205.
87. Gomez Ravetti M, Moscato P. Identification of a 5-protein biomarker molecular signature for predicting Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003; 74: 1200-1205.
88. Reich RR, Lengacher CA, Klein TW, Newton C, Shivers S, Ramesar S, et al. A randomized controlled trial of the effects of Mindfulness-Based Stress Reduction (MBSR[BC]) on levels of inflammatory biomarkers among recovering breast cancer survivors. Biol Res Nurs. 2017; 19: 456-464.
89. Cahn BR, Goodman MS, Peterson CT, Maturi R, Mills PJ. Yoga, Meditation and mind-body health: increased bdnf, cortisol awakening response, and altered inflammatory marker expression after a 3-month yoga and meditation retreat. Front Hum Neurosci. 2017; 11: 315.
90. Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: A comparative overview. Mol Neurobiol. 2014; 50: 534-544.
91. Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis. 2012; 30: 559-572.
92. Meyer PF, Savard M, Poirier J, Labonte A, Rosa-Neto P, Weitz TM, et al. Bi-directional association of cerebrospinal fluid immune markers with stage of Alzheimer’s Disease pathogenesis. J Alzheimers Dis. 2018; 63: 577-590.
93. Hooper C, De Souto Barreto P, Cantet C, Cesari M, Payoux P, Salabert AS, et al. Chronically raised C-reactive protein is inversely associated with cortical beta-amyloid in older adults with subjective memory complaints. Exp Gerontol. 2018; 108: 226-230.
94. Pace TW, Negi LT, Adame DD, Cole SP, Sivilli TI, Brown TD, et al. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology. 2009; 34: 87-98.
95. Chouinard AM, Larouche E, Audet MC, Hudon C, Goulet S. Mindfulness and psychoeducation to manage stress in amnestic mild cognitive impairment: A pilot study. Aging Ment Health. 2019; 23: 1246-1254.
96. Debruyne H, Van Buggenhout M, Le Bastard N, Aries M, Audenaert K, De Deyn PP, et al. Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? Intern J Geriatr Psychiat. 2009; 24: 556-562.

97. Evans J, Charness N, Dijkstra K, Fitzgibbons JM, Yoon JS. Is episodic memory performance more vulnerable to depressive affect in older adulthood? Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2019; 26: 244-263.